PharmiWeb.com - Global Pharma News & Resources

Company Directory

PharmiWeb's Pharma Company Directory is a comprehensive and searchable listing of organisations within the pharma industry. Use it to find partner organisations, suppliers, or even a company to work for!

As an organisation, a basic listing is FREE, and can raise your profile in the industry, making you visible to thousands of monthly site visitors.

To add your organisation to the directory, simply register as a contributor and add your organisation's details. You can also upgrade to a premium listing for only £500/year, this offers even greater scope for added content (more photos, more links, more copy), and even more exposure.

Note that we only accept contributions relating to the Pharma industry and that it will typically take 2 working days to approve (or otherwise) your details. Once approved, you will also be able to contribute press releases and event details to our site.

Create a free account to list your company for free!

Our teams are highly successful at consistently advocating for our customers, engaging with applicants about your roles, using tried and tested methods.
Synexus, Acurian, and Optimal are now AES. AES owns the most fully identified patient data. And we own the world’s largest network of clinical research sites.
AI & Medicine has proudly developed a unique artificial intelligence drug research and development platform to offer drug development solutions for worldwide customers from the medical institutions and pharmaceutical enterprises.
Why ÅKRN as Your Medical Device CRO? We are flexible, agile, and with solid medical device expertise. We offer optimized regulatory and clinical services tailored to our clients and MedTech partners.
Al Solutions (Al2S3) is backed by well-known industry experts. We are dedicated to making a real difference to the Life Science recruitment and staffing industry.
ASLAN Pharmaceuticals is a clinical-stage oncology and immunology focused biopharmaceutical company developing novel therapeutics for global markets. We target diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.